Neuralstem, Inc. (CUR): Neuralstem rises after announcing start of stem cell trial – Seeking Alpha
| Seeking Alpha Neuralstem rises after announcing start of stem cell trial. The University of Michigan has treated the first two patients in a Phase II trial testing the effectiveness of Neuralstem’s (CUR +5.9%) NSI-566 neural stem cells in treating ALS (Lou Gehrig’s … University Of Michigan Health System Treats Its First Patients In Neuralstem’s …PR Newswire (press release) |
